Important: PDUFA.BIO is not the FDA. ODIN scores are ML model outputs, not financial advice. All investing carries risk. Read full disclaimer โ†’

PDUFA.BIO
Tue Mar 3, 2026
12 this week

FDA PDUFA Calendar & Biotech Catalyst Intelligence โ€” Scored by AI

Track every upcoming PDUFA date, Phase 2/3 readout, and biotech earnings event in one fast, filterable calendar. PDUFA.BIO's ODIN scoring engine analyzes 2,200+ historical FDA decisions to generate real-time approval probability scores โ€” so you can size positions with conviction, not guesswork.

50 PDUFA dates186 phase readouts27 earnings datesUpdated 3/3/2026

FDA Catalyst Intelligence

ML probability scores for PDUFA dates & Phase 2/3 readouts. Powered by ODIN v1108 โ€” 54-weight engine trained on 2,210 PDUFAs. AUC 0.88.

CATALYSTS: 263|VERIFIED: 51/53 CORRECT|UPDATED: Mar 3, 2026|โ— LIVE
๐Ÿ†
LATEST WIN: ASND +6%TIER_1ODIN 88.9%5d AGO
Navepegritide (YUVIWEL) โ€” Achondroplasia (Pediatric). Accelerated approval 1 day before PDUFA (Feb 27 vs Feb 28). First weekly CNP analog for achondroplasia in children 2+. Orphan Drug. Rare Pediatric Dis
+6%
How to Use ODIN3 steps to your first trade
ODIN Verified Track Record
51/5396.2%TIER_1: 27/28 (96.4%)
Every prediction SHA-256 hashed before FDA decisions
Top TIER_1 Catalysts โ€” March 2026
Highest probability FDA approvals
1.
GSKLinerixibatPDUFA
Cholestatic Pruritus (PBC)
93.6%
Mar 24
2.
BMYDeucravacitinib (Sotyktu)PDUFA
Psoriatic Arthritis
90.7%
Mar 6
3.
LNTHGallium-68 edotreotidePDUFA
NET PET Imaging
86.0%
Mar 29
๐Ÿ”ฅODIN CAPITAL
COMING MID-MARCH

Real money. Real markets. ODIN Capital brings live trading powered by the same ML engine scoring every catalyst on this dashboard. Paper trade now to sharpen your edge before launch.

ODIN-Scored EntriesAuto Risk SizingCatalyst AlertsOptions Flow
Why PDUFA.BIOvs. alternatives
FeaturePDUFA.BIOOthers
AI Approval Predictionsโœ… ODIN (TIER_1 96.4%)โš ๏ธ Manual only
SHA-256 Hash Proofโœ… Pre-lockedโŒ No verification
Verified Track Recordโœ… 51/53 (96.2%)โŒ No public record
Runup Timing Strategyโœ… T-25โ†’T-7 optimizedโš ๏ธ Generic
Real-Time Updatesโœ… Instant alertsโš ๏ธ Varies
Priceโœ… Free tierโš ๏ธ $$$
ACTIVE CATALYSTS
263
50 PDUFA ยท 186 Readouts ยท 27 Earnings
HIGH CONVICTION
168
96 T1 ยท 72 T2 (PDUFA only)
AVG PDUFA PROB
74.9%
NEXT 7 DAYS
12
Next: VSTM

Next Upcoming Catalysts

ASND โ€” Navepegritide (TransCon CNP) (PDUFA) โ€” 2026-02-28 โ€” ODIN: 88%
BMRN โ€” PALYNZIQ (pegvaliase) (PDUFA) โ€” 2026-02-28 โ€” ODIN: 92%
CHRS โ€” Idebenone (PDUFA) โ€” 2026-02-28 โ€” ODIN: 81%
EOLS โ€” Q4 2025 Earnings (Earnings) โ€” 2026-03-03
QSI โ€” Q4 2025 Earnings (Earnings) โ€” 2026-03-03

NEXT CATALYST EVENT

TIER 1

Deucravacitinib (Sotyktu)

Bristol-Myers Squibb (BMY)

Psoriatic Arthritis

90.7%
ODIN Approval Probability
COUNTDOWN TO DECISION
0
days
:
00
hrs
:
00
min
:
00
sec
Fri, Mar 6, 2026 ยท UTC ยท Target 5 PM ET
TIER DISTRIBUTION (PDUFA only)
26
12
6
6
TIER 1: 26TIER 2: 12TIER 3: 6TIER 4: 6
NEXT 30 DAYS โ€” 41 EVENTS
Mar 4, 2026 (Est.)VSTMAfter Market Close
Mar 4, 2026 (Est.)VEEVAfter Market Close
Mar 4, 2026 (Est.)ICCCAfter Market Close
Mar 4, 2026 (Est.)OCGNBefore Market Open
Mar 5, 2026 (Est.)COOAfter Market Close
Mar 5, 2026 (Est.)PROFAfter Market Close
Mar 5, 2026 (Est.)OPRXAfter Market Close
Mar 5, 2026 (Est.)TNGXBefore Market Open
Mar 5, 2026 (Est.)HCMBefore Market Open
Mar 6, 2026BMY90.7%

PDUFA.BIO

FDA catalyst intelligence powered by the ODIN v1108 scoring engine. Trained on 2,200+ PDUFA decisions & 2,000+ phase readouts (2015โ€“2026).

PLATFORM

LEARN

PDUFA.BIO is the data-driven FDA PDUFA calendar and biotech catalyst calendar built for quantitative investors. Track upcoming PDUFA dates for 2026, FDA drug approval action dates, and biotech earnings dates in a unified, filterable calendar. Learn what a PDUFA date is and how the ODIN AI scoring engine generates FDA approval probability scores. Use the biotech catalyst screener to filter by ticker, therapeutic area, and ODIN tier. Explore the PDUFA runup strategy and verify ODIN's accuracy on the verified track record page. Browse our biotech glossary and catalyst research hub.

DISCLAIMER: PDUFA.BIO is not affiliated with, endorsed by, or connected to the U.S. Food & Drug Administration (FDA) or any government agency. The name "PDUFA" refers to the Prescription Drug User Fee Act and is used descriptively. This site does not provide financial, investment, legal, or medical advice. PDUFA.BIO is not a registered investment advisor, broker-dealer, or financial planner. Probability scores are generated by machine-learning models based on historical data and publicly available information. These scores are statistical estimates, not predictions or guarantees of FDA action or securities performance. Past approval rates do not guarantee future results.

RISK WARNING: Investing in biotechnology and pharmaceutical securities involves substantial risk, including the risk of total loss of capital. Binary catalyst events (such as PDUFA dates) can result in extreme price volatility. You should not invest money you cannot afford to lose. Always consult with a qualified financial advisor before making investment decisions. PDUFA.BIO, its operators, contributors, and affiliates accept no responsibility or liability for any losses arising from use of this site.

ยฉ 2026 PDUFA.BIO โ€” All rights reserved.Market data via FMP ยท Social data via LunarCrush